Cost & Access

Compounded Tirzepatide vs Brand Mounjaro: Cost, Safety, and What to Know in 2026

GLP-1 Companion · 9 min read

Brand-name tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for obesity — costs over $1,000 per month without insurance. For the millions of Americans who cannot get insurance coverage for these medications or cannot afford the out-of-pocket cost, compounded tirzepatide has emerged as a compelling alternative. Searches for "compound tirzepatide" have exploded in 2025 and 2026.

But the regulatory and safety landscape around compounded tirzepatide is more complex — and more rapidly changing — than for compounded semaglutide. Here is what you need to know.

What Is Compounded Tirzepatide

Compounded medications are prepared by licensed compounding pharmacies, which create customized formulations outside of the standard FDA drug approval process. Compounding pharmacies have historically served patients with specific medical needs that commercial formulations cannot meet — such as patients who need a different dose, a different delivery method, or a formulation without a specific allergen.

Compounded tirzepatide uses the same active molecule as Mounjaro and Zepbound but is manufactured by the compounding pharmacy rather than by Eli Lilly. The compound may be supplied as a vial that the patient draws into a syringe rather than the auto-injector pen used by brand-name products.

How Much Does Compounded Tirzepatide Cost vs Brand Mounjaro

• Brand Mounjaro (Eli Lilly): $1,000-$1,200/month without insurance
• Brand Zepbound (Eli Lilly): $550-$1,100/month without insurance (vial option available)
• Compounded tirzepatide: $200-$500/month depending on dose and pharmacy

The cost difference is significant — many patients report paying 50-75% less for compounded versions. This price advantage is what drives the search interest.

Is Compounded Tirzepatide Legal

This is the most nuanced part of the compounded tirzepatide story, and the answer has changed over time.

Under federal law (the FD&C Act), compounding pharmacies may compound drugs that are on the FDA's drug shortage list. When tirzepatide (Mounjaro) was on the official FDA shortage list in 2023-2024 due to high demand, compounding of tirzepatide was broadly permitted. Eli Lilly resolved the shortage, and the FDA removed tirzepatide from the shortage list in 2024.

After removal from the shortage list, the FDA moved to restrict compounded tirzepatide:

• The FDA issued guidance that compounding of tirzepatide by state-licensed (503A) pharmacies is not permitted once the shortage is resolved
• The FDA gave 503A pharmacies a compliance period to wind down tirzepatide compounding
• Some 503B outsourcing facilities continued compounding tirzepatide under different regulatory provisions, subject to ongoing FDA review
• Regulatory enforcement and court challenges to the FDA's actions have created ongoing uncertainty

Is Compounded Tirzepatide the Same as Mounjaro

At the molecular level, compounded tirzepatide contains the same active ingredient. However, there are meaningful differences in the product:

• Manufacturing oversight: Eli Lilly's manufacturing facilities undergo extensive FDA inspection and quality auditing. Compounding pharmacies have different regulatory oversight levels depending on whether they are 503A (state-licensed) or 503B (federally registered outsourcing facility).
• Formulation: Brand Mounjaro uses a specific proprietary formulation. Compounded versions may differ in excipients (inactive ingredients), pH buffering, preservatives, and concentration.
• Delivery device: Brand Mounjaro and Zepbound use auto-injectors for consistent dosing. Compounded tirzepatide typically requires the patient to draw the dose into a syringe — user error risk is higher.
• Stability and storage: Compounded products may have different shelf lives and stability profiles than the commercial product.

Safety Concerns With Compounded Tirzepatide

The FDA has documented specific safety concerns with compounded semaglutide and tirzepatide:

• Incorrect dosing: Vial-and-syringe systems rely on patients and providers accurately calculating doses. Unit confusion errors (mcg vs mg) have led to overdoses resulting in hospitalizations.
• Contamination: The FDA has issued warnings about some compounded GLP-1 products with contamination or stability issues.
• Unlicensed suppliers: Some online platforms have sold tirzepatide products without requiring valid prescriptions or ensuring the source is a licensed pharmacy.
• Additives: Some compounded products include additional ingredients (B12, L-carnitine) not studied in combination with tirzepatide.

None of these risks mean compounded tirzepatide is inherently dangerous when obtained from a legitimate, licensed 503B facility under the care of a physician. But they are meaningful risks that do not exist with a brand-name auto-injector obtained from a regulated pharmacy.

Brand Mounjaro vs Brand Zepbound: Which Brand Should You Choose

For patients who want brand-name tirzepatide, Mounjaro and Zepbound contain the same active ingredient at the same doses. The difference is the approved indication and therefore insurance coverage:

• Mounjaro: Approved for type 2 diabetes. Insurance typically covers it for diabetes diagnosis.
• Zepbound: Approved for obesity/overweight with weight-related conditions. Insurance coverage is less consistent but expanding.
• Eli Lilly offers Zepbound in vials at lower cost than auto-injectors — approximately $349-$499/month through the LillyDirect program.

What Is LillyDirect and Can It Help

Eli Lilly launched LillyDirect as a direct-to-patient pharmacy option for Zepbound. Through LillyDirect, Zepbound vials are available for $349-$499/month (depending on dose) for self-pay patients — substantially below the auto-injector list price. This program has partially addressed the cost-driven demand for compounded alternatives, though the price remains out of reach for many patients.

Who Might Consider Compounded Tirzepatide

Compounded tirzepatide may be appropriate for patients who:

• Have confirmed that compounding is legal and compliant in their state at the time of purchase
• Obtain it through a 503B-registered, FDA-compliant outsourcing facility
• Are under the care of a prescribing physician who manages their dosing and monitoring
• Have been unable to obtain or afford brand-name tirzepatide through other channels

The Bottom Line

Compounded tirzepatide offers meaningful cost savings over brand Mounjaro and Zepbound and has been used by large numbers of patients with reported effectiveness. The key risks are regulatory uncertainty (the FDA's enforcement position is evolving), quality differences from brand-name manufacturing, and dosing errors with vial-based systems. Always work with a licensed prescriber and verify the legitimacy of any pharmacy before obtaining compounded medications.

Sources

• FDA: Compounded Tirzepatide Products
• LillyDirect: Zepbound Self-Pay Vials
• SURMOUNT-1: Tirzepatide for Obesity (NEJM 2022)
• FDA Warning on Compounded GLP-1 Products